Translational medicine in action, and validation for the MesenFlow strategy. Mesenchymal factors regulate human CD16+ monocyte function in chronic inflammation and cancer. https://t.co/fSnaphicE5
MesenFlow Technologies is proud to be part of a study on circadian rhythms in leukocyte trafficking, published in @ImmunityCP. What a fantastic way to end the year.
We wish our friends and colleagues a Happy New Year for 2019!
https://t.co/k0V3AMvJHx
Commentary on the publication in Nature Comms, with the founders of MesenFlow Technologies. Applying powerful and deliverable translational technologies to cancer therapy. https://t.co/lmZM5jXzRy
Valdiating a translational approach in the treatment of cancer & chronic inflammation. A radio interview with author Adama Sidibe about a recent publication in Nature Comms. Further validation of the MesenFlow strategy (In French). https://t.co/FONS2e5AYN via @RadioTeleSuisse
@stuartacook1 Good to see you on Twitter. All a bit new to me. Maybe this link is of interest to you in CV disease and chronic inflammation? Regards, Paul https://t.co/fSnaphzNvD